CCRA Adverse Event Management 3

Question 1

What is a Data Safety Monitoring Board (DSMB) and its primary function in clinical trials?

Accepted Answer

An independent committee that periodically reviews accumulating safety data to protect subject welfare and trial integrity

Answer

A regulatory body that approves IND applications

Answer

A sponsor department responsible for AE database entry

Answer

A group of site staff who manage local safety reporting

Question 2

When grading the severity of adverse events in oncology trials, which standard grading system is most commonly used?

Accepted Answer

NCI Common Terminology Criteria for Adverse Events (CTCAE)

Answer

WHO Toxicity Scale

Answer

Likert Pain Scale

Answer

CIOMS Severity Index

Question 3

What is the purpose of an annual Development Safety Update Report (DSUR)?

Accepted Answer

To provide a comprehensive annual review of the investigational product's safety profile and risk-benefit assessment

Answer

To document site initiation activities for the year

Answer

To report financial expenditures to regulatory agencies

Answer

To submit enrollment data to the trial registry

Question 4

If a subject experiences an SAE after the last dose of investigational product, during the follow-up period specified in the protocol, the investigator should:

Accepted Answer

Report the SAE to the sponsor per protocol-specified timelines since it occurred during the defined follow-up window

Answer

Not report the SAE since the subject is no longer receiving study drug

Answer

Only report the SAE if the investigator believes it is drug-related

Answer

Wait for the next monitoring visit to discuss the event with the CRA

Question 5

The MedDRA coding system is used in clinical trials to:

Accepted Answer

Standardize medical terminology for adverse event classification and regulatory reporting

Answer

Assign billing codes for insurance reimbursement

Answer

Code laboratory values for statistical analysis

Answer

Classify investigational products by pharmacological class

Question 6

Unblinding of treatment assignment in a blinded trial for safety reporting purposes should:

Accepted Answer

Follow a pre-defined emergency unblinding procedure that minimizes unnecessary unblinding while protecting subject safety

Answer

Never occur under any circumstances

Answer

Be performed by the CRA for all SAEs

Answer

Require FDA approval before execution